Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Immunotherapy. University Medical Center Mannheim, Mannheim, Germany

Survival: 12.3 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Germany
City/State/Province: Mannheim
Hospital: University Medical Center Mannheim
Journal: Link
Date: 8/2008

Patients: This phase 2 study involved 112 patients with stage IIIB or IV non-small cell lung cancer. They were divided into two treatment groups. One group had a median age of 65, the other was 67 years of age.

Treatment: Patients were treated with taxane (docetaxel or paclitaxel) and platinum-based (carboplatin or cisplatin) chemotherapy drugs alone or with chemotherapy and an immunotherapy PF-3512676. PF-3512676 is a small molecule that stimulates the immune system.

Toxicity: The most common grade 4 toxicity was neutropenia, which occurred in 57% of patients treated with chemotherapy and immunotherapy, and in 24% of patients treated with chemotherapy alone. Grade 4 toxicities occurring in less than 10% of patients included fatigue, dehydration, weakness, abdominal pain, anemia, leucopenia, and thrombocytopenia. Grade 4 toxicities were more common in the group of patients treated with both chemotherapy and immunotherapy.

Results: The median survival was 12.3 months for patients treated with the immunotherapy PF-3512676 and chemotherapy, and 6.8 months for those treated with chemotherapy alone.

Support: This study was supported by Coley Pharmaceutical Group, Inc., and Pfizer Pharmaceuticals Inc. These companies respectively developed and licensed PF-3512676.

Correspondence: Dr. Christian Manegold

E-mail to a Friend Email Physician More Information